Lys250
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.0
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys250  -  BUB1B (human)

Site Information
IRVGGALkAPSQNRG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 7761217

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 2 , 3 ) , mass spectrometry ( 3 ) , modification-specific antibody ( 2 , 3 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 1 , 2 , 3 )
Disease tissue studied:
multiple myeloma ( 1 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 1 , 3 ) , HeLa (cervical) ( 2 , 3 ) , KMS-12-BM (B lymphocyte) ( 1 ) , MEF (fibroblast) ( 2 ) , NCI-H929 (B lymphocyte) ( 1 ) , SNU-1393-SC ( 1 )

Upstream Regulation
Regulatory protein:
BRCA2 (human) ( 2 )
Treatments:
MG132 ( 2 ) , nocodazole ( 2 , 3 ) , siRNA ( 2 , 3 )

Downstream Regulation
Effects of modification on BUB1B:
protein stabilization ( 2 , 3 ) , ubiquitination ( 3 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 2 ) , cell cycle regulation ( 2 , 3 )

References 

1

Park J, et al. (2021) Loss of BubR1 acetylation provokes replication stress and leads to complex chromosomal rearrangements. FEBS J 288, 5925-5942
33955658   Curated Info

2

Choi E, et al. (2012) BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation. Dev Cell 22, 295-308
22340495   Curated Info

3

Choi E, et al. (2009) BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis. EMBO J 28, 2077-89
19407811   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.